Ad
Wednesday, 25 July 2018
Biogen/Eisai Alzheimer's drug cuts cognitive decline 30 percent: study
Biogen Inc and partner Eisai Co Ltd said patients with early-stage Alzheimer's disease treated with their experimental drug BAN2401 experienced 30 percent less cognitive decline than those who got a placebo in a highly anticipated midstage trial.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment